Belgium· BE-AMP-SAM540124-00
Mulpleo 3 mg
A lusutrombopag product containing lusutrombopag, registered in Belgium by Shionogi Europe. The same ATC class is registered in 7 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Lusutrombopag is registered in 7 of 19 countries.
Countries holding a registration under ATC B02BX07 (lusutrombopag), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 4 of them publish a price we can compare per daily dose
Lusutrombopag · ATC B02BX07
7 / 19 countries
- Belgiumprice
- Finlandprice
- Ireland
- Japan
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Lusutrombopag
- Manufacturer
- Shionogi Europe
- Country
- Belgium (BE)
- ATC code
- B02BX07
- ATC class
- Lusutrombopag
- Defined daily dose
- 3 mg, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
164 interactions on record for lusutrombopag.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lusutrombopag · interactions on record
164 records
- 2 severe
- 162 moderate
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- RolapitantA04AD14moderate
- FidaxomicinA07AA12moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lusutrombopag in 6 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3bf2c5a5-7971-4148-bcf7-e0c7cd243093 GET /v1/drugs/3bf2c5a5-7971-4148-bcf7-e0c7cd243093?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"source": "afmps",
"status": "REVOKED",
"name_en": "Mulpleo 3 mg",
"name_fr": "Mulpleo 3 mg",
"name_nl": "Mulpleo 3 mg",
"amp_code": "SAM540124-00",
"strengths": [
"3.0000",
"3.0000"
],
"pack_count": 1,
"substances": [
"Lusutrombopag",
"Mannitol",
"Sodium Laurilsulfate"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Lusutrombopag",
"authorisation_numbers": [
"EU/1/18/1348/001"
]
}See everything about lusutrombopag.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.